According to study conducted by Shimizu et al., GSK-3β is essential for the development of acquired resistance to lorlatinib in ALK-positive NSCLC, which is mediated by lorlatinib intermediate-resistant cells. Here, ALK is linked to non-small cell lung carcinoma.